Estudio plato ticagrelor pdf

In the platelet inhibition and patient outcomes plato trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after acs, but increased the incidence of dyspnea, which may lead clinicians to. Cardiovascular events in acute coronary syndrome patients. Pdf longterm costeffectiveness of ticagrelor versus. Listing a study does not mean it has been evaluated by the u. In a substudy of plato, 199 subjects underwent pulmonary function testing irrespective of whether they reported. Safety and efficacy of prasugrel and ticagrelor in acute. Prehospital ticagrelor in stsegment elevation myocardial. Socrates acute stroke or transient ischaemic attack. Plato n 18,624 was a multicentre, doubleblind, randomized trial in acs, that showed a 16% reduction in cardiovascular death cvdeath, myocardial infarction mi and stroke with ticagrelor compared with clopidogrel, without significant increase in overall major bleeding. Ticagrelor in patients with st elevation myocardial. The plato study evaluated the efficacy of adding ticagrelor, instead of clopidogrel, to aspirin in patients with acute coronary syndrome, which showed surprisingly positive results making the drug. Longterm costeffectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in spain.

Sabatine, md, mph, brigham and womens hospital boston, massachusetts although the era of coronary artery reperfusion in the acute phase of myocardial infarction mi was initiated with the introduction of thrombolytic therapy, it has remained an inadequate treatment because it fails to achieve complete infarctrelated artery patency in a large percentage of. Estudio plato hemorragias mayores a 18624 sca 12 meses nejm 2009. In this sense, patients randomized to ticagrelor received the first dose of ticagrelor several hours after initiation of fibrinolytic therapy median, 11. Nov 21, 2014 ticagrelor in patients with st elevation myocardial infarction treated with pharmacological thrombolysis treat the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Plato shows that treatment with ticagrelor as compared with clopidogrel in patients with acute coronary syndromes significantly reduced the rate of death from vascular causes, myocardial. Mortality was reduced with ticagrelor, as compared with clopidogrel, in the large plato trial. Ticagrelor versus clopidogrel in asian patients with acute. Oct 09, 2015 in the platelet inhibition and patient outcomes plato trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after acs, but increased the incidence of dyspnea, which may lead clinicians to withhold ticagrelor from copd patients. Ticagrelor vs clopidogrel after fibrinolytic therapy in. Ticagrelor is the latest naa to be incorporated into clinical practice, and therefore there are few studies to date evaluating the realworld use of this drug. The plato trial was a phase 3, randomized, doubleblind, parallelgroup, multinational, clinical study comparing the efficacy of ticagrelor formerly known as azd6140, marketed as brilinta versus standard care treatment with clopidogrel. Socrates acute stroke or transient ischaemic attack treated with aspirin or ticagrelor and patient outcomes socrates the safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes n engl j med 2009. Socrates acute stroke or transient ischaemic attack treated. Nov 26, 20 risk for major bleeding in patients receiving ticagrelor compared with aspirin after transient ischemic attack or acute ischemic stroke in the socrates study acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes. Atherosclerosis is an ongoing process affecting mainly large and mediumsized arteries. Ticagrelor in patients with st elevation myocardial infarction treated with pharmacological thrombolysis treat the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. For most included patients, randomized treatment did not begin immediately but rather hours after initiation of fibrinolytic therapy. Ticagrelor gonzalez gero my, martinez garcia rm, caniego rodrigo md. Abstract background the relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain. Ticagrelor versus clopidogrel in patients with acute coronary. The data, taken alongside plato and pegasustimi 54, suggest that dual antiplatelet therapy with aspirin and ticagrelor is effective in patients with acute coronary syndrome and previous mi as well as in stable cad patients with diabetes who had previously undergone pci, say investigators.